Drug Trial News

RSS

Combining tiotropium with olodaterol significantly improves lung function in COPD patients

New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol significantly improved lung function (FEV1) over 24 hours in COPD patients compared to olodaterol alone.

3 Sep 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Boehringer Ingelheim presented today for the first time data from a Phase II dose ranging study investigationg the combination of olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA), in COPD patients, compared to the investigational agent olodaterol alone.

3 Sep 2012

Tiotropium improves lung function in symptomatic asthma patients on ICS/LABA

Data from the PrimoTinA-asthma Phase III studies presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that tiotropium significantly reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICSB/LABAC.

3 Sep 2012

Sosei highlights data from QVA149 clinical trials on COPD

Sosei Group Corporation highlights that further data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs were presented today by Novartis at the European Respiratory Society (ERS) Congress.

3 Sep 2012

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

Boehringer Ingelheim presented today the first data from the Phase III UniTinA-asthma program. In two studies, presented at the 2012 European Respiratory Society (ERS) Congress in Vienna, Austria, tiotropium delivered once daily via the Respimat inhaler significantly improved lung function and reduced asthma exacerbations in patients who remained symptomatic on current treatment with at least high dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).

3 Sep 2012

SPIRIVA to mark 10th anniversary with European Respiratory Society Congress

Coinciding with the annual European Respiratory Society Congress, ERS 2012, SPIRIVA (tiotropium), the first once-daily long-acting inhaled anticholinergic maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) will mark its 10th anniversary since launch.

3 Sep 2012

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) – at the annual meeting of the European Respiratory Society in Vienna, Austria.

3 Sep 2012

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Sophiris Bio Inc. today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

1 Sep 2012

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

1 Sep 2012

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.

31 Aug 2012

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Transition Therapeutics Inc. today announced that its licensing partner, Elan Corporation, plc has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.

31 Aug 2012

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix, Inc., a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

31 Aug 2012

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.

31 Aug 2012

Sosei’s QVA149 Phase III study on COPD meets primary endpoint

Sosei Group Corporation confirms the information released today by Novartis that results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide.

31 Aug 2012

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Belimumab has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). Products (AMNOG).

30 Aug 2012

Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).

30 Aug 2012

Protalex announces results from PRTX-100 Phase 1b trial on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including rheumatoid arthritis (RA), today announced results from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

30 Aug 2012

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

Drug Trial News

Combining tiotropium with olodaterol significantly improves lung function in COPD patients

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Tiotropium improves lung function in symptomatic asthma patients on ICS/LABA

Sosei highlights data from QVA149 clinical trials on COPD

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

SPIRIVA to mark 10th anniversary with European Respiratory Society Congress

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Sosei’s QVA149 Phase III study on COPD meets primary endpoint

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects

Protalex announces results from PRTX-100 Phase 1b trial on active rheumatoid arthritis

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News